{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:05:05Z","timestamp":1793397905586,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"name":"the Heilbrunn Family Center for Research Nursing at the Rockefeller University"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"\n OBJECTIVE:<\/jats:title>\n To examine gestational weight gain and pregnancy outcomes (eg, gestational diabetes, preterm birth) among individuals with overweight or obesity who had semaglutide exposure before and during pregnancy.<\/jats:p>\n <\/jats:sec>\n \n METHODS:<\/jats:title>\n \n This is a retrospective cohort study using a national-level dataset that links electronic medical record and pharmacy dispensing data (Truveta). Women with prepregnancy overweight or obesity who delivered between January 2022 and January 2026 were classified into three groups based on semaglutide use: 1) pregnancy-exposed users (before and into pregnancy), 2) former users (before pregnancy only), and 3) nonusers.\n Preterm birth<\/jats:italic>\n was defined as delivery between 24 and 37 completed weeks of gestation. Gestational diabetes, pregnancy-related hypertension, intrauterine growth restriction, excessive fetal growth, and cesarean delivery were identified using International Classification of Diseases, Tenth Revision codes. To reduce confounding, 1:1 propensity score matching was performed based on maternal age, race and ethnicity, prepregnancy body mass index (BMI), prepregnancy diabetes, and prepregnancy hypertension. In the matched cohorts, linear and logistic regression models were used with additional adjustment for residual confounding.\n <\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n Pregnancy-exposed users (n=429) had a mean age of 32.7\u00b14.9 years at delivery, a mean prepregnancy BMI of 36.9\u00b16.8, and a median total exposure time in pregnancy of 44 days. Compared with nonusers (n=2,203), pregnancy-exposed users had higher risk of excessive gestational weight gain (adjusted odds ratio [aOR]=2.88, 95% CI, 2.04\u20134.05), gestational diabetes (aOR=1.59, 95% CI, 1.03\u20132.44), excessive fetal growth (aOR=1.78, 95% CI, 1.03\u20133.08), and cesarean delivery (aOR=3.35, 95% CI, 2.15\u20135.22). Similarly, former users (n=801) also had higher risks of excessive gestational weight gain (aOR=1.98, 95% CI, 1.56\u20132.51), gestational diabetes (aOR=1.43, 95% CI, 1.05\u20131.93), excessive fetal growth (aOR=1.54, 95% CI, 1.01\u20132.36), and cesarean delivery (aOR=3.92, 95% CI, 2.81\u20135.47) compared with nonusers. No statistically significant differences in gestational weight gain or pregnancy outcomes were observed between pregnancy-exposed users and former users.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSION:<\/jats:title>\n Semaglutide exposure prior to and during pregnancy was associated with higher risks of adverse pregnancy outcomes compared with no semaglutide use. There were no differences when comparing those who discontinued prior to or during pregnancy, suggesting that the elevated risks are more likely attributable to rebound effects after treatment discontinuation rather than to intrauterine exposure itself.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/aog.0000000000006325","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:01:23Z","timestamp":1780002083000},"page":"229-237","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Gestational Weight Gain and Pregnancy Outcomes After Semaglutide Exposure"],"prefix":"10.1097","volume":"148","author":[{"given":"Yang","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan W.","family":"Groth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnin","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana M.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Phelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie J.","family":"Hollenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Dreisbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"R1-20260824","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/AOG.0000000000004395","article-title":"Obesity in pregnancy. ACOG Practice Bulletin No. 230. American College of Obstetricians & Gynecologists","volume":"137","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R2-20260824","doi-asserted-by":"crossref","first-page":"e12972","DOI":"10.1111\/obr.12972","article-title":"Guidelines for the management of pregnant women with obesity: a systematic review","volume":"21","author":"Simon","year":"2020","journal-title":"Obes Rev"},{"key":"R3-20260824","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz","year":"2024","journal-title":"Am J Cardiol"},{"key":"R4-20260824","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"R5-20260824","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/AOG.0000000000006161","article-title":"Prescribing trends in glucagon-like peptide-1 medications among pregnant and postpartum persons","volume":"147","author":"Lessard","year":"2026","journal-title":"Obstet Gynecol"},{"key":"R6-20260824","doi-asserted-by":"crossref","first-page":"e2457232","DOI":"10.1001\/jamanetworkopen.2024.57232","article-title":"Longitudinal analysis of obesity drug use and public awareness","volume":"8","author":"Berning","year":"2025","journal-title":"JAMA Netw Open"},{"key":"R9-20260824","doi-asserted-by":"crossref","first-page":"E268","DOI":"10.1152\/ajpendo.00361.2023","article-title":"Maternal GLP-1 receptor activation inhibits fetal growth","volume":"326","author":"Qiao","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R10-20260824","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.2147\/DDDT.S484531","article-title":"Semaglutide alleviates ovary inflammation via the AMPK\/SIRT1\/NF-\u03baB signaling pathway in polycystic ovary syndrome mice","volume":"18","author":"Liu","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"R11-20260824","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.2147\/DDDT.S522730","article-title":"Semaglutide alleviates ovarian oxidative stress and autophagy via the PI3K\/AKT\/mTOR pathway in mice with polycystic ovary syndrome","volume":"19","author":"Guo","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"R13-20260824","doi-asserted-by":"crossref","first-page":"114836","DOI":"10.1016\/j.ejogrb.2025.114836","article-title":"Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review","volume":"317","author":"Mandal","year":"2026","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R14-20260824","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjcard.2025.03.013","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonist use during the first trimester in pregnant women with type 2 diabetes","volume":"246","author":"Hanif","year":"2025","journal-title":"Am J Cardiol"},{"key":"R15-20260824","doi-asserted-by":"crossref","first-page":"hoag015","DOI":"10.1093\/hropen\/hoag015","article-title":"Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study","volume":"2026","author":"Hviid","year":"2026","journal-title":"Hum Reprod Open"},{"key":"R16-20260824","doi-asserted-by":"crossref","first-page":"e70021","DOI":"10.1111\/bcpt.70021","article-title":"Pregnancy outcomes after semaglutide exposure","volume":"136","author":"Kolding","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R17-20260824","doi-asserted-by":"crossref","first-page":"e083550","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six teratology information services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"R18-20260824","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1001\/jama.2025.20951","article-title":"Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation","volume":"334","author":"Maya","year":"2025","journal-title":"JAMA"},{"key":"R19-20260824","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/AOG.0000000000005995","article-title":"Gestational weight gain and hypertensive disorders of pregnancy with prepregnancy and early pregnancy glucagon-like peptide-1 receptor agonist exposure","volume":"147","author":"Pondugula","year":"2026","journal-title":"Obstet Gynecol"},{"key":"R20-20260824","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Int Med"},{"key":"R21-20260824","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40618-025-02792-1","article-title":"Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study","volume":"49","author":"le Roux","year":"2026","journal-title":"J Endocrinol Invest"},{"key":"R22-20260824","doi-asserted-by":"crossref","first-page":"111317","DOI":"10.1016\/j.contraception.2025.111317","article-title":"Evaluating changes in lidocaine and opioid administration on the day of IUD insertion, 2018-2025","volume":"156","author":"Masters","year":"2026","journal-title":"Contraception"},{"key":"R23-20260824","doi-asserted-by":"crossref","first-page":"e2551814","DOI":"10.1001\/jamanetworkopen.2025.51814","article-title":"Delayed or absent first dose of measles, mumps, and rubella vaccination","volume":"9","author":"Masters","year":"2026","journal-title":"JAMA Netw Open"},{"key":"R24-20260824","doi-asserted-by":"crossref","first-page":"e0284893","DOI":"10.1371\/journal.pone.0284893","article-title":"Identification of pregnancies and their outcomes in healthcare claims data, 2008-2019: an algorithm","volume":"18","author":"Ailes","year":"2023","journal-title":"PLoS One"},{"key":"R26-20260824","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R27-20260824","doi-asserted-by":"crossref","first-page":"103680","DOI":"10.1016\/j.eclinm.2025.103680","article-title":"Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis","volume":"90","author":"Tzang","year":"2025","journal-title":"EClinicalMedicine"}],"container-title":["Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:00:54Z","timestamp":1787572854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006325","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"2025-08-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}